Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,629 GBX | -0.67% | -7.78% | +12.33% |
12:02am | US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 | RE |
Jun. 07 | GSK says FDA Approves Expanded Age Indication For Arexvy, RSV Vaccine For Adults Aged 50-59 At Increased Risk | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company has a low valuation given the cash flows generated by its activity.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.33% | 84.52B | B | ||
+45.82% | 765B | C+ | ||
+40.95% | 632B | B | ||
-6.16% | 354B | C+ | ||
+19.86% | 331B | B- | ||
+9.32% | 299B | C+ | ||
+18.45% | 248B | B+ | ||
+11.88% | 216B | B- | ||
-0.78% | 219B | A+ | ||
+5.90% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GSK Stock
- Ratings GSK plc